1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
1
Active Trials
200 recruiting
2
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Shenzhen Celconta Life Science Co.Ltd is a company with 1 orphan drug designation across 2 rare diseases. Active clinical trials in 1 indication. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| breast cancer | - | Des.TrialAppr. |
| hepatocellular carcinoma | peripheral blood mononuclear cell (PBMC) derived allogeneic natural killer (NK) cell | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
10
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
10
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
1
affecting portfolio